FLOW Trial Explained: Semaglutide Kidney Outcomes and Tracking

Why kidney outcomes matter on a GLP-1

Many people who use a GLP-1 tracker app care first about weight, appetite or blood sugar notes. Kidney health sits next to those goals for a large share of adults with type 2 diabetes. The U.S. National Institute of Diabetes and Digestive and Kidney Diseases explains that chronic kidney disease often develops slowly and may have few early symptoms, which is why providers watch lab trends over time rather than a single reading.

In 2024, a large outcomes study called FLOW reported how once-weekly semaglutide compared with placebo for major kidney events in people who already had type 2 diabetes and chronic kidney disease. The results were published in the New England Journal of Medicine and later informed a U.S. label update for one semaglutide product. This post summarizes what FLOW measured, what the authors reported, and how a careful personal record can support the conversation with a licensed healthcare provider. It is educational. It is not medical advice, and it does not tell anyone what medicine or schedule to use.

What FLOW studied

FLOW enrolled adults with type 2 diabetes and chronic kidney disease defined by estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR) ranges set in the protocol. Participants were randomized to once-weekly subcutaneous semaglutide at 1.0 mg or matching placebo, on top of usual care that typically included a renin-angiotensin system blocker when that was tolerated. Median follow-up was about 3.4 years after the trial stopped early for efficacy at a planned interim look.

The primary outcome was a composite of major kidney disease events: kidney failure (dialysis, transplant, or sustained eGFR below 15), a sustained drop of at least 50% in eGFR from baseline, or death from kidney-related or cardiovascular causes. Confirmatory secondary outcomes included the kidney-specific pieces of that composite, the annual eGFR slope, major cardiovascular events, and death from any cause.

Those details matter for readers who track labs at home. FLOW was not a short weight-loss study. It was an event-driven kidney outcomes trial in a higher-risk diabetes population. Findings from FLOW apply to the population and product studied. They do not automatically answer every question about other GLP-1 medicines, obesity without diabetes, or compounding.

What the FLOW results reported

Among 3,533 participants, the primary composite occurred less often with semaglutide than with placebo. The published hazard ratio was 0.76 (95% CI 0.66 to 0.88), described as a 24% lower risk of a first primary-outcome event. Kidney-specific components and cardiovascular death also favored semaglutide in the published analyses. The mean annual eGFR decline was slower with semaglutide by about 1.16 mL/min/1.73 m². Major cardiovascular events and all-cause death were also lower in the semaglutide group in the confirmatory hierarchy.

Serious adverse events were reported in a lower percentage of participants on semaglutide than on placebo in the published report. As with other GLP-1 research, gastrointestinal effects remain a common reason people discuss tolerability with their provider. MedlinePlus notes that semaglutide products can cause nausea, vomiting, diarrhea and related effects, and that kidney problems can worsen when fluid loss is severe. That is another reason providers often ask for both dose timing and symptom notes, not weight alone.

Again, these numbers describe a trial population under protocol care. Individual results vary. A licensed healthcare provider is the person who judges whether a given medicine and monitoring plan fit a specific patient.

How FLOW connects to everyday tracking

If you already use a semaglutide tracker or a broader GLP-1 log, FLOW points to a practical recording habit: keep the same lab names and units next to your dose history so trends are easy to show.

Useful items many clinics already request:

• eGFR and creatinine dates, with the lab name if you have it
• UACR or other urine albumin results when your clinic orders them
• Blood pressure readings if you measure at home
• Weight on a consistent scale and time of day
• On-time versus missed dose marks for the schedule your provider gave you
• Side-effect check-ins (mild to severe) on days that felt different
• Other kidney-related medicines your provider listed, so the record matches the chart

None of those fields tells you what to take. They help you describe what already happened. When eGFR moves after a change in food intake, illness, diuretics or a new medicine, a dated note next to the lab can save a long reconstruction at the visit.

Building a record a nephrology or primary-care visit can use

A clean export or screen history beats a pile of screenshots. Aim for a short timeline:

1. Date of each dose you logged, and whether it was on time or missed
2. Date and value for each eGFR or UACR result you received
3. Weight and blood pressure on the same calendar when you track them
4. Symptom tags that match how you felt that week
5. Questions you want to ask, written before the appointment

If your provider changes the dose they prescribed, record the new instruction as they stated it. Do not invent a step. Tools that store a titration ladder only hold the steps you enter from the clinic plan. For syringe or vial math on a separate powder preparation, a free peptide calculator can turn vial strength, water added and the dose your provider gave you into volume and units. It converts the numbers you enter. It does not choose a medicine or a dose.

Peppy can keep dose history, weight, side-effect check-ins and reminders in one place on the iPhone, which makes the appointment packet easier to assemble. The educational value of FLOW still stands if you prefer a spreadsheet. The point is dated, consistent fields your provider can scan quickly.

What FLOW does not settle

FLOW does not mean every person on any GLP-1 will see the same kidney result. It studied once-weekly semaglutide 1.0 mg versus placebo in type 2 diabetes with defined CKD. It does not replace ACE inhibitors, ARBs, SGLT2 inhibitors or other standard kidney care your clinic may already use. It does not diagnose kidney disease from a home log. And it does not tell you to start, stop or change any medicine.

If labs move, or if vomiting and poor fluid intake show up together, contact the clinician who manages your care. Tracking supports that conversation. It does not replace it.

A simple checklist after reading FLOW

• Confirm with your provider which kidney labs they want and how often
• Store each result with the date beside your dose history
• Keep weight and side-effect notes on the same timeline when those matter for your plan
• Bring missed-dose context instead of averages alone
• Ask how your personal eGFR and UACR trend compares with the goals they set for you

FLOW widened the evidence base for semaglutide in diabetes-related chronic kidney disease. A GLP-1 tracker that sits next to those labs turns a headline into a visit your provider can use.

Sources

• Perkovic V et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024. PubMed 38785209
• National Institute of Diabetes and Digestive and Kidney Diseases. Chronic Kidney Disease (CKD). NIDDK
• MedlinePlus. Semaglutide Injection. MedlinePlus a618008